Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Cybin Inc (CYBN.NE)

Cybin Inc (CYBN.NE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NEO]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NEO]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 88,796
  • Shares Outstanding, K 176,560
  • Annual Sales, $ 0 K
  • Annual Income, $ -67,631 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.37
Trade CYBN.NE with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.33
  • Most Recent Earnings -0.06 on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4000 +32.50%
on 01/05/23
0.8300 -36.14%
on 01/10/23
+0.1150 (+27.71%)
since 12/30/22
3-Month
0.3750 +41.33%
on 12/21/22
0.8300 -36.14%
on 01/10/23
-0.0900 (-14.52%)
since 10/28/22
52-Week
0.3750 +41.33%
on 12/21/22
1.5000 -64.67%
on 08/31/22
-0.7700 (-59.23%)
since 01/28/22

Most Recent Stories

More News
Cybin (NEO: CYBN) (NYSE American: CYBN) Announces Virtual R&D Day

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has scheduled a virtual R&D Day for Feb. 28, 2023; the event is scheduled...

CYBN.NE : 0.5200 (+4.00%)
CYBN : 0.3921 (-1.98%)
Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry

EQNX::TICKER_START (OTCQB:LOBEF),(NASDAQ:ATAI),(NASDAQ:CMPS),(NYSE:CYBN),(NASDAQ:MNMD) EQNX::TICKER_END

CYBN.NE : 0.5200 (+4.00%)
MMED.NE : 4.6400 (+1.53%)
LOBEF : 0.0300 (-2.28%)
LOBE.CN : 0.0400 (unch)
ATAI : 1.8100 (+1.12%)
CMPS : 10.60 (-0.93%)
CYBN : 0.3921 (-1.98%)
MNMD : 3.48 (+1.16%)
Cybin to Host Virtual R&D Day on February 28, 2023

Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® today announced that it will host a virtual...

CYBN.NE : 0.5200 (+4.00%)
CYBN : 0.3921 (-1.98%)
Cybin Announces Promising Results from Sponsored Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® today announced key highlights from the completed...

CYBN.NE : 0.5200 (+4.00%)
CYBN : 0.3921 (-1.98%)
Cybin (NYSE American: CYBN) (NEO: CYBN) Selects Generalized Anxiety Disorder as Target Indication for CYB004

Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(R). The company today announced that it has selected Generalized Anxiety Disorder...

CYBN.NE : 0.5200 (+4.00%)
CYBN : 0.3921 (-1.98%)
Cybin Selects Generalized Anxiety Disorder as Target Indication for Deuterated DMT Molecule CYB004

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) ( Cybin or the Company ), a biotechnology company focused on progressing Psychedelics to Therapeutics ® today announced that it has selected Generalized...

CYBN.NE : 0.5200 (+4.00%)
CYBN : 0.3921 (-1.98%)
Cybin (NEO: CYBN) (NYSE American: CYBN) Releases Update on Clinical Programs

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), is discussing upcoming priorities and near-term milestones regarding the status...

CYBN.NE : 0.5200 (+4.00%)
CYBN : 0.3921 (-1.98%)
Cybin Outlines Upcoming Priorities and Milestones for its Clinical Development Programs

Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® today outlined its upcoming priorities and near-term...

CYBN.NE : 0.5200 (+4.00%)
CYBN : 0.3921 (-1.98%)
Cybin (NYSE American: CYBN) (NEO: CYBN) CEO Highlights 2022 as ‘Momentous Year’

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today issued a year-end summary of its key milestone accomplishments in 2022....

CYBN.NE : 0.5200 (+4.00%)
CYBN : 0.3921 (-1.98%)
Cybin Highlights 2022 Accomplishments and Milestones

Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , is pleased to provide a year-end summary of...

CYBN.NE : 0.5200 (+4.00%)
CYBN : 0.3921 (-1.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Key Turning Points

3rd Resistance Point 0.5500
2nd Resistance Point 0.5400
1st Resistance Point 0.5200
Last Price 0.5200
1st Support Level 0.4900
2nd Support Level 0.4800
3rd Support Level 0.4600

See More

52-Week High 1.5000
Fibonacci 61.8% 1.0702
Fibonacci 50% 0.9375
Fibonacci 38.2% 0.8047
Last Price 0.5200
52-Week Low 0.3750

See More

Business Summary

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems,...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar